Logo do repositório
 
Publicação

Evaluation of Tissue and Circulating miR-21 as Potential Biomarker of Response to Chemoradiotherapy in Rectal Cancer

2020-09-14Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorOurô, Susana
dc.contributor.authorMourato, Cláudia
dc.contributor.authorFerreira, Marisa P.
dc.contributor.authorAlbergaria, Diogo
dc.contributor.authorCardador, André
dc.contributor.authorCastro, Rui E.
dc.contributor.authorMaio, Rui
dc.contributor.authorRodrigues, Cecília M. P.
dc.date.accessioned2023-05-18T18:10:20Z
dc.date.available2023-05-18T18:10:20Z
dc.date.issued2020-09-14
dc.date.updated2022-08-30T14:36:50Z
dc.description.abstractResponse to chemoradiotherapy (CRT) in patients with locally advanced rectal cancer (RC) is quite variable and it is urgent to find predictive biomarkers of response. We investigated miR-21 as tissue and plasma biomarker of response to CRT in a prospective cohort of RC patients; The expression of miR-21 was analyzed in pre- and post-CRT rectal tissue and plasma in 37 patients with RC. Two groups were defined: Pathological responders (TRG 0, 1 and 2) and non-responders (TRG 3). The association between miR-21, clinical and oncological outcomes was assessed; miR-21 was upregulated in tumor tissue and we found increased odds of overexpression in pre-CRT tumor tissue (OR: 1.63; 95% CI: 0.40–6.63, p = 0.498) and pre-CRT plasma (OR: 1.79; 95% CI: 0.45–7.19, p = 0.414) of non-responders. The overall recurrence risk increased with miR-21 overexpression in pre-CRT tumor tissue (HR: 2.175, p = 0.37); Significantly higher miR-21 expression is observed in tumor tissue comparing with non-neoplastic. Increased odds of non-response is reported in patients expressing higher miR-21, although without statistical significance. This is one of the first studies on circulating miR-21 as a potential biomarker of response to CRT in RC patients.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.doi10.3390/ph13090246pt_PT
dc.identifier.issn1424-8247
dc.identifier.slugcv-prod-2006784
dc.identifier.urihttp://hdl.handle.net/10451/57467
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relation03/SAICT/2015 Programas de Atividades Conjuntaspt_PT
dc.relationPRECISION ONCOLOGY BY INNOVATIVE THERAPIES AND TECHNOLOGIES
dc.relation.publisherversionhttps://www.mdpi.com/1424-8247/13/9/246pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectBiomarkerspt_PT
dc.subjectmiR-21pt_PT
dc.subjectChemoradiotherapypt_PT
dc.subjectRectal cancerpt_PT
dc.subjectTherapy responsept_PT
dc.subjectTumor regression gradept_PT
dc.titleEvaluation of Tissue and Circulating miR-21 as Potential Biomarker of Response to Chemoradiotherapy in Rectal Cancerpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitlePRECISION ONCOLOGY BY INNOVATIVE THERAPIES AND TECHNOLOGIES
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/9471 - RIDTI/SAICTPAC%2F0019%2F2015/PT
oaire.citation.issue9pt_PT
oaire.citation.startPage246pt_PT
oaire.citation.titlePharmaceuticalspt_PT
oaire.citation.volume13pt_PT
oaire.fundingStream9471 - RIDTI
person.familyNameOurô
person.familyNameMourato
person.familyNameCastro
person.familyNameRodrigues
person.givenNameSusana
person.givenNameCláudia
person.givenNameRui
person.givenNameCecilia
person.identifierA-4524-2019
person.identifier30919
person.identifier.ciencia-idE917-6239-02B4
person.identifier.ciencia-id2D17-6370-AA84
person.identifier.ciencia-id3C1C-A6C2-71ED
person.identifier.ciencia-idDC18-39A7-F287
person.identifier.orcid0000-0002-0764-6694
person.identifier.orcid0000-0002-7805-4346
person.identifier.orcid0000-0002-7417-0091
person.identifier.orcid0000-0002-4829-754X
person.identifier.ridI-2975-2013
person.identifier.ridM-3572-2013
person.identifier.scopus-author-id7202085681
person.identifier.scopus-author-id7202508239
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.cv.cienciaid2D17-6370-AA84 | Cláudia Mourato
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationecf8fdbe-b2a9-4602-9b94-4dba568c4c76
relation.isAuthorOfPublicationb8d60c59-208c-45cc-adba-991f01ef9425
relation.isAuthorOfPublicationfcf09dfd-d4a8-4818-840d-bc2f1ae2b690
relation.isAuthorOfPublicatione207ba8d-b67d-4f67-bbf4-d0858977a052
relation.isAuthorOfPublication.latestForDiscoveryb8d60c59-208c-45cc-adba-991f01ef9425
relation.isProjectOfPublication7a25b129-19f8-47b3-a119-0c46d8e0bc70
relation.isProjectOfPublication.latestForDiscovery7a25b129-19f8-47b3-a119-0c46d8e0bc70

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
pharmaceuticals-13-00246.pdf
Tamanho:
931.11 KB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

FF - CiênciaVitae - Faculdade de Farmácia